anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Transdermal therapeutic system for topical and systemic application of active agents includes at least one compound chosen from cpds. (A), from which nitrogen oxide is released by human or animal metabolism and cpds (B) which release NO in the organism. Nitrate esters and molsidomin are specifically excluded. Pref. compsn. contains arginine or a deriv., a cpd. with a gp. SNO, (a) or (b), a cpd. of formula (I), a sodium nitroprusside, or nitroso iron (II) sulphate, R1 and R2 = 1-12C alkyl without an branch, or benzyl, or NR1R2 = pyrrolidino, piperidino, piperazino or morpholine; an M&lt;x+&gt; = a cation; and x = the valency of the cation. USE/ADVANTAGE - The compsn. is used to treat NO- deficiency, high blood pressure, arterial spasms, platelet aggregation arteriosclerosis, to influence immunological and inflammatory process, to improve transfer of around signals in the central and peripheral nervous system, to relax the corpus cavernosum and to combat tumour cells. The compsn. releases the active agent steadily over a long time.
1394981 Incinerators NICHOLS ENG &amp; RESEARCH CORP 1 Oct 1973 [6 Oct 1972] 45695/73 Heading F4B An incinerator for sewage scum has a lower tank portion 12. an ignition chamber 14 above the tank and in communication with it, and an upper combustion chamber 16 communicating with the ignition chamber 14, the tank 12 having an inlet 18 for a continuous flow of sewage consisting of floatable solids in water and an outlet controlling the liquid level in the tank, ignition burners 50 and air nozzles 52, 62 in the chamber 14 and nozzles 78 for combustion air in chamber 16, the products of combustion being discharged through a gas scrubber with a lower outlet for solid materials and an upper outlet for exhaust gases. As the sewage flows through the tank oleaginous solids rise to the surface and, after twelve or more hours, sufficient has accumulated to be burned. The floated scum is agitated by fingers 42 rotating with shaft 44. The roof of chamber 14 is a shallow dome having a passage 72 in the middle. A baffle 74 over the upper end of passage 72 causes the combustion gases from chamber 14 to enter chamber 16 radially and mix with combustion air from tangentiallydirected jets 78. Fully burnt gases leave chamber 16 via passage 86 and are drawn downwardly through a duct with a butterfly control valve and a cooler to a blower which forces the gases through a water scrubber to a chimney.
The present invention relates to a method of using slow and controlled release technology for preparing a slow and controlled release preparation of helicidum. The proportion of the helicidum which is a main medicine to a medical adjuvant material is from 1 to 4:1 to 8. The helicidum and the adjuvant material are mixed to be made into globular fine particles of which the diameters are from 0.5mm to 3mm to be loaded into empty capsules or pressed into tablets. The unit content of the helicidum in the preparation is from 25 to 150 mg. The condition of a plurality of administration times per day can be changed into the condition of one or two administration times per day. The user&#39;s compliance is improved, and compared with that of the conventional preparation and in the patient&#39;s medical administration period, the present invention excellently keeps the stable blood medical level in the human body. The technical defects that the conventional preparation has high fluctuation of the blood medical level with a peak valley phenomenon, particularly when the blood medical level is high (a peak state), strong side effect is generated, and even severe poisoning is generated, and when the blood medical level is too low (a valley state), the concentration is lower than a treating concentration, and thus, the treating effect can not be performed or guaranteed, etc., are avoided.
N,N-dimethyl p-dimethylamino phenyl ethylamine bis methiodide is prepared by reacting thionyl chloride with p-dimethylaminodihydrocinnamic acid.  The product is treated with sodium azide in acetone, and then with hydrochloric acid, to form p-dimethylaminophenylethylamine, which is subsequently treated with methyl iodide.  The bis methiodide may also be prepared by reacting methyl iodide with a methanol solution of beta-p-aminophenylethylamine.  N,N-dimethyl beta p-dimethylaminophenylethylamine bis ethiodide is prepared by methylating p-dimethylaminophenylethylamine and then treating with ethyl iodide.ALSO:A pharmaceutical preparation possessing ganglionic blocking activity contains, in association with a compatible non-toxic diluent, a bis quaternary salt containing the cation &lt;FORM:0705506/VI/1&gt; where R represents methyl or ethyl.  A tablet or elizir is preferred.  Examples relate to the preparation of N:N- dimethyl ppdimethylaminophenylethyl-amine bis methiodide m.pt. 255 DEG C and the bis ethiodide m.pt. 200 DEG C (see Group IV(b)).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an osteoporosis preventive-therapeutic agent and an osteoclast differentiation inhibitor, both including an extract which is obtained by cultivating kudzu (Pueraria lobata) and stably extracting a functional component (isoflavones, etc.) from kudzu stem at a high production efficiency.  &lt;P&gt;SOLUTION: Both of the osteoporosis preventive-therapeutic agent and the osteoclast differentiation depressant include, as the effective component, a lignified current-year&#39;s living stem itself gathered in a large amount in kudzu cultivation and including a large amount of the functional component (isoflavones, etc.), or include the extract of the living stem. A drug medicine, a food and drink, etc., prepared by compounding the osteoporosis preventive-therapeutic agent or the osteoclast differentiation depressant, are also provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a simple method for producing a thermoplastic polymer for inexpensively feeding polymer micro-particles having a narrow particle size distribution breadth and ≤50 μm average particle diameter using a general-purpose polymer as a raw material without relying on the degree of polymerization.  &lt;P&gt;SOLUTION: The micro-particles are composed of a thermoplastic addition polymer containing a raw material of an unsaturated compound which is a gas at normal temperature and having ≥10,000 molecular weight or are composed of a thermoplastic polycondensate and have ≤50 μm average particle diameter, a narrow particle size breadth and a spherical to a spheroidal shape with a smooth surface. In the micro-particles, the raw material of the unsaturated compound which is the gas at normal temperature is preferably at least one kind of ethylene, propylene, isopropylene and butylene. The micro-particles are used for light scattering for diffusion films, a slippery effective agent for cosmetics and an anti-blocking agent. The method for producing the polymer micro-particles comprises cooling and solidifying a system in which a molten polymer and a dispersion medium form a metastable emulsion under shear stress in a state maintaining the emulsion.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A method for inducing differentiation of monocytes contained in an extracorporeal quantity of a subject&#39;s blood into functional dendritic antigen presenting cells is provided. The monocytes are induced to differentiate into dendritic cells by activation forces resulting from flow of the monocytes through a treatment apparatus having plastic channels. The interior surface of the plastic channel may be modified to increase the available surface area for interaction with blood monocytes. Platelets and serum protein may be removed from the blood prior to treatment to reduce or eliminate contamination of the plastic channel by these blood components. Functional dendritic cells generated from induced monocytes are incubated together with apoptotic or inactivated disease effector agents to enhance the presentation of at least one disease-causing antigen expressed by the disease effector agents. Compositions including dendritic cells derived from induced monocytes and compositions including such dendritic cells incubated with disease effector agents are also provided for use in immunotherapeutic treatment.
The present invention pertains to a novel cell based tumor vaccine platform. The invention provides a method for modifying antigen presenting cells (APCs) to present both MHC class I and/or MHC class II peptides in context of improved peptide presentation protein complexes in order to increase activation of a patient&#39;s immune response. In this invention, an MHC II mRNA dendritic cell based vaccine platform was developed to activate CD4 +  T cells in patients and to enhance the anti-tumor response. The invariant chain (Ii) was modified and the semi-peptide CLIP was replaced with an MHC II binding peptide sequences of tumor associated antigens. These chimeric MHC II constructs are presented by APCs and induce proliferation of tumor specific CD4 +  T cells. The invention provides the constructs, proteins, nucleic acids, recombinant cells, as well as medical applications of these products.
An application of oroxylin A and a pro-drug thereof as a catechol-type medicine synergist belongs to the technical field of medicines. The compound is used as the catechol-type medicine synergist and has the following structure general formula (I), wherein R is hydrogen, carboxylic ester, glucuronic acid and the like substitutive groups. One or more compounds of the oroxylin A and the pro-drug thereof can be mixed with levodopa according to a certain ratio to prepare a drug composition for treatment of Parkinson&#39;s disease. The oroxylin A and the pro-drug prepared through modification thereof are improved in both solubility and transmembrane capability and are significantly prolonged in in-vivo metabolic half life period, which is longer than the in-vivo metabolic half life periods of majority of catechol-type medicines, so that the compounds have excellent medicine preparation prospect. In addition, the compounds also can be combined with a catechol-type medicine to form a compound medicine. The compound medicine can be prepared into an oral-taking slow-release preparation to further improve oral-taking bioavailability and treatment effects of the catechol-type medicines.
PURPOSE:To obtain (+ or -)-trans-chrysanthenol useful as an intermediate for novel optically active chrysanthevols for perfumery by reducing (+ or -)-chrysanthenone with an alkali metal in liquid ammonia in the presence of a hydrogen donor. CONSTITUTION:(+ or -)-trans-Chrysanthenol of the formula B is easily produced in a high yield by reducing (+ or -)-chrysanthenone of the formula A with an alkali metal in liquid ammonia in the presence of a hydrogen donor. The (+ or -)-trans- chrysanthenol can be resolved to optically active (-)-trans-chrysanthenol and (+)-trans-chrysanthenol by an optical resolution operation using an optically active camphoric acid as a resolution agent. A corresponding optically active ester can be produced by introducing a lower-alkanoyl group to the compound. In the above compounds, the compound of the formula I (R&lt;1&gt; is H or lower alkanoyl) and the compound of the formula II or the formula III [R&lt;2&gt; is (S)-(-) or (R)-(+)-camphanoyl] are new compounds. A perfumery composition is prepared by using the new compound of the formula I or the formula IV as an active component.
PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient&#39;s age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.
PROBLEM TO BE SOLVED: To efficiently obtain baicalin and baicalein in a Chinese crude medicine such as Scutellaria root, etc., containing no admixture, by supercritical chromatography using a concentration gradient method with an alcohol and/or water as an auxiliary solvent. SOLUTION: An alcohol solution and/or an aqueous solution obtained by mixing and dissolving baicalin and baicalein is subjected to supercritical chromatography using a concentration gradient method with an alcohol and/or water as an auxiliary solvent. Ethanol is preferable as the alcohol and carbon dioxide is preferable as the supercritical fluid. Preferably, the amount of the auxiliary solvent is 5-20ml based on 1mg of baicalin and baicalein and that of carbon dioxide is 300-500ml in terms of economic efficiency. The temperature in the supercritical chromatography is 308.15-313.15K and the pressure is preferably 15-25MPa. The measuring flow velocity is adjusted to 5ml.minute&lt;-1&gt; , that of an eluting solution to 0.1-0.5ml.minute&lt;-1&gt; and the concentration gradient is prepared therefor.
PURPOSE:To provide an external agent for skin, such as base cosmetic, makeup cosmetic, hair cosmetic, drug, quasi-drug, etc., containing urea in a state of improved age stability, by compounding specific hydroquinone glycoside together with urea. CONSTITUTION:The objective external agent for skin contains 1pt.wt. of urea and &gt;=1/10pts., preferably &gt;=1pt. of a hydroquinone glycoside of formula (R is pentose residue, hexose residue, amino sugar residue, uronic acid residue or their methylated products) (especially preferably hydroquinone-beta-D-glucose). The amount of urea in the whole drug composition is 0.1-20wt% and that of the hydroquinone glycoside is 0.1-30wt%, preferably 6-20wt%. The effect can be effectively exhibited especially in an aqueous system containing urea in the form of an aqueous solution (provided that the substrate is preferably acidic).
The invention discloses a medicine for treating snake wound. The medicine consists of an internal medicine and an external application medicine. The external application medicine comprises the following drugs by weight: 100 parts of jiangducao, 100 parts of borneol, 100 parts of realgar, 350 parts of zaoqi, 50 parts of Spiranthes sinensis (Pers.) Ames and 100 parts of Hemiboeasubcapitata Clarke. The above drugs are prepared into powders by a conventional pharmaceutical method, then uniformly mixed together according to the above-mentioned parts by weight, and finally blended into a paste by a proper amount of vinegar. The internal medicine comprises the following drugs by weight: 50 parts of jiangducao, 60 parts of Polygonum aviculare, 60 parts of desmodium, 50 parts of the shell of areca nut, 30 parts of dragon&#39;s blood, 40 parts of Cortex Phellodendri, 100 parts of licorice, 50 parts of Scutellaria baicalensis, and 30 parts of Coptis chinensis. Each of the drugs is produced into a powder by a conventional pharmaceutical method, and then the drugs are uniformly mixed and compacted into pellets according to the above-mentioned weight ratio. The invention has the advantages of good treatment effect, and low cost of treatment.
A portable device for storing and providing access to a user&#39;s medical and demographic information. The portable storage device allow a medical provider immediate access to the user&#39;s current medical, demographic, and insurance information without the need to ask questions or fill out written forms. A system and method of using the portable storage device includes a customer portal hosted on a remote server that is accessible to the user. The user can create and update their electronic user record on the portal as needed. The medical provider can access the electronic user record via an external device interface at the point of service. The external device interface may communicate with a local electronic medical record system and may update the electronic user record on the portable storage device following an appointment.
1527638 Oil-based suspensions of niclosamide BAYER AG 14 Dec 1976 [20 Dec 1975] 52104/76 Heading A5B Orally administrable pharmaceutical or veterinary anthelmintic compositions consist of an oil-based suspension of niclosamide (2-hydroxy-5-2&#39;-dichloro-4&#39;-nitrobenzanilide) or a salt thereof, in which at least 50% of the particles of niclosamide or its salt are smaller than 2Á. The active compound may be anhydrous or contain water of crystallisation, and may be in the form of its piperazine (also anthelmintically active) salt. The composition may contain a surface-active agent (e.g. lecithin or a polyoxyethylated sorbitan monolaurate, or other anionic, cationic, ampholytic or non-ionic surfactants. Suitable oils are liquid paraffin and/or sesame oil. The compositions are prepared by grinding the niclosamide in the oil until the required particle size is reached, and optionally adding further oil and/or a surface active agent. The compositions are said to have improved storage stability and anthelmintic activity.
A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. Such compositions may be used to treat hepatic and genetic disorders related to copper overload. Multiple other compounds may be added with the instant claimed compounds and may be delivered as a pharmaceutical dose suitable for treating Wilson&#39;s disease. (I) R 1 , R 2 , and R 3 each independently represents hydrogen, thiol, alkyl, alkyl thiol, acetyl thiol, disulfide, acyl, acylalkyl, alkenyl, alkyl thioalkyl, alkynyl, alkoxyaryl, alkoxyalkyl, aryl, aralkyl, aryloxyalkyl, arylthioalkyl, cycloalkyl, ether, ester, heteroaryl, heterocyclyl, lower alkyl, sulfone, sulfoxide, or hydroxyalkyl; and R4 represents at least one of a residue of guanidine, a residue of hydrazine, an acid, a residue of pyruvic acid, a residue of oxaloacetic acid, a residue of tocopherol, a residue of ascorbic acid, a residue of thiamine, thioctic acid, a residue of thioctic acid, a residue of acetyl cysteine, a residue of alpha-keto glutaric acid, a residue of dimercaprol, a residue of an NO donor, a residue of glutathione, (RS)-2, 3-disulfanylpropan-l-ol, (R)-2-acetamido-3- sulfanylpropanoic acid and an analog of any one of the foregoing.
Novel 5,10-seco-steroids of the formulae &lt;FORM:1065432/C2/1&gt; &lt;FORM:1065432/C2/2&gt; (wherein R and R3 are each two hydrogen atoms, an oxo group or a hydrogen and an a - or b -hydroxyl group; R1 and R5 each is an oxo group or an alkylenedioxy group of at most 4 carbon atoms or a hydrogen and an a - or b -free, esterified or etherified hydroxyl group; R2 is oxo, or alkylenedioxy of at most 4 carbon atoms, or hydrogen or an aliphatic hydrocarbon radical of at most 6 carbon atoms and a b -free, esterified or etherified hydroxyl group; R4 and R6 each is hydrogen or a free, esterified or etherified hydroxyl group; and X is hydrogen, fluorine, chlorine or bromine) and their 1(10)-dehydro derivatives, and the 4(5)-dehydro and 1(10), 4(5)-bisdehydro derivatives of the 5-unsubstituted compounds; are prepared by reacting a corresponding 5-hydroxy steroid that contains no further oxidizable hydroxyl group with an oxidizing tetravalent lead acylate or with a compound that contains monovalent positive iodine and, if desired, in the resulting 5-oxo-5,10-seco-D 1(10)-steroids the double bond and/or the oxo group is hydrogenated and/or any protected hydroxyl or oxo groups are liberated and/or any free oxo group is eliminated and/or a 5-hydroxyl group is eliminated to form a D 4-double bond and/or free hydroxyl groups are esterified or etherified. Resulting 5-hydroxy steroids can be re-oxidized to the 5-ketones.  5-Hydroxy-steroids used as starting materials are prepared by reducing 5,6-oxido-steroids. Any free oxo groups reduced in this process are subsequently re-formed by oxidation.  The 5-10-seco-steroids of the invention, which are stated to be useful as androgens, anabolics, progestatives and as agents capable of regulating the mineral metabolism and the blood cholesterol level, may be made up into pharmaceutical or veterinary compositions with suitable carriers, for parenteral, enteral or local administration. They may contain preserving, stabilizing, wetting or emulsifying agents, salts for regulating the osmotic pressure, or buffers.
PURPOSE:To obtain a sustained suppository capable of maintaining a drug level in blood and providing simple operation in production with hardly any irritation to mucous membranes by blending a large amount of sucrose ester of a fatty acid with further an oily phase ingredient. CONSTITUTION:A suppository obtained by blending 30-40wt.% sucrose ester of a fatty acid [preferably a monoester, diester or polyester of sucrose with an 8-20C higher fatty acid (e.g. palmitic or stearic acid) or a mixture thereof having &lt;=8 HLB value] with an oily phase ingredient (e.g. higher fatty acid triglyceride, lanolin fat, cacao fat or liquid paraffin) and a drug effect ingredient (e.g. a drug, such as antipyretic and analgesic agent or antibiotic substance, normally used in the suppository). The above-mentioned suppository is prepared by mixing and melting the sucrose ester of the fatty acid and oily phase ingredient at 70-90 deg.C, adding the drug effect ingredient, thoroughly mixing the afore- mentioned ingredients, filling the resultant mixture in a container and rapidly cooling the mixture.
FIELD: medicine, biotechnology, pharmacology. SUBSTANCE: invention relates to peptide antagonists of zonuline. Invention involves peptide antagonists of zonuline as they determined in the invention claim that bind with receptors of zone of narrow contacts (zonula occludens) but don&#39;t modulate opening narrow contacts of mammalian cells. The advantage of invention involves the competitive inhibitory effect of indicated antagonists on binding toxin Zonula Occludens with its receptor resulting to inhibition of toxin ability and zonuline to modulate opening narrow contacts in mammals physiologically. EFFECT: valuable properties of antagonist. 8 dwg, 4 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and a composition relating to two classes of semaphorin receptors, SR1 and SR2.  &lt;P&gt;SOLUTION: The cDNA encoding semaphorin receptor derived from a rat and a human are acquired. Animal cell (COS-7,293) is transformed and expressed by using the same. SR-specific binding agents (for treating, search for pharmaceutical, etc.) are obtained by synthesis of a peptide comprising the specific sequence. The polypeptides may be produced recombinantly from transformed host cells from the SR encoding nucleic acids or purified from human cells.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain the subject preparation, capable of increasing the decomposed amount of a fat (a triglyceride) in fat cells and useful for locally slimming a site where the fats are readily accumulated such as the abdominal part, the thigh part or the buttocks by including a specific phosphoric acid as an active ingredient therein. SOLUTION: This preparation is obtained by including adenosine 3&#39;,5&#39;-cyclic phosphate (hereinafter abbreviated to cAMP) as an active ingredient. The cAMP is extracted from Zizyphus vulgaris Lam. Var. inermis Bunge or Zizyphi Inermi Fructus or the like with ethanol, 1,3-butylene glycol or the like. An adequate amount of the preparation at 0.1-0.5 mg/L concentration is preferably locally applied one to three times a day and sufficient massage is preferably carried out. The dosage form is preferably a cream, a lotion or the like.